B-1654

N/A

Report date: 2025/06/17 17:51:58

Base Information

Drug NameB-1654
Drug Alias NameB-1654
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionFibroblast growth factor 21 modulators
TargetsFibroblast growth factor 21
Therapy Area/IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTianjin Tasly Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Tasly Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A